Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. (APRE) Insider Trading
Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.
SEC EDGAR · FMP · APRE · as of Jun 9, 2026
Activity summary
Buy transactions
16
P-Purchase only
Sell transactions
0
12 Months
Buy/Sell ratio
∞
Buy/Sell (by trades)
Overall sentiment
Aprea Therapeutics, Inc. insiders have been net buyers of shares over the past 12 Months, which may signal confidence in the company's outlook.
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only
As of Jun 9, 2026
APRE insider buying and selling by quarter
APRE insider selling · APRE insider buying stocks · quarterly insider activity
Mobile shows last 4Q · Desktop shows full 8Q
▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters
As of Jun 9, 2026
Active insiders
Most active in past 12 months · APRE ceo insider trading
Showing all insiders · Click a card to filter the transactions table below
▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API
Recent insider transactions
APRE executive sell shares · APRE board member insider trading · APRE insider trading SEC filing
Scroll horizontally to see all columns
| Date | Insider | Type | Shares | Value | Filing |
|---|---|---|---|---|---|
| Mar 12, 2026 | Gilad Oren President/CEO · Director | Award | 20,175 | — | Form 4 |
| Mar 12, 2026 | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | Award | 10,095 | — | Form 4 |
| Jan 30, 2026 | Gilad Oren President/CEO · Director | Purchase | 28,100 | $25K | Form 4 |
| Jan 30, 2026 | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | Purchase | 5,700 | $5K | Form 4 |
| Dec 10, 2025 | Duey Marc Director | Purchase | 21,459 | $25K | Form 4 |
| Dec 10, 2025 | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | Purchase | 5,000 | $6K | Form 4 |
| Jun 5, 2025 | Seizinger Bernd R. Director | Award | 1,045 | — | Form 4 |
| Jun 5, 2025 | Peters Richard Director | Award | 1,045 | — | Form 4 |
| Jun 5, 2025 | Pamukcu Rifat Director | Award | 1,045 | — | Form 4 |
| Jun 5, 2025 | HENNEMAN JOHN B III Director | Award | 1,045 | — | Form 4 |
| Jun 5, 2025 | Gruia Gabriela Director | Award | 1,045 | — | Form 4 |
| Jun 5, 2025 | Grissinger Michael Director | Award | 1,045 | — | Form 4 |
| Jun 5, 2025 | Duey Marc Director | Award | 1,045 | — | Form 4 |
| Jun 5, 2025 | BIZZARI JEAN-PIERRE Director | Award | 1,045 | — | Form 4 |
| Apr 3, 2025 | Gilad Oren President/CEO · Director | Purchase | 2,497 | $4K | Form 4 |
| Apr 3, 2025 | Gilad Oren President/CEO · Director | Purchase | 3,003 | $6K | Form 4 |
| Mar 27, 2025 | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | Award | 3,365 | — | Form 4 |
| Mar 27, 2025 | Gilad Oren President/CEO · Director | Award | 6,725 | — | Form 4 |
| Oct 18, 2024 | Duey Marc Director | Sale | 6,462 | $30K | Form 4 |
| Oct 23, 2024 | Gilad Oren President/CEO · Director | Purchase | 500 | $2K | Form 4 |
| Oct 16, 2024 | Duey Marc Director | Purchase | 30,000 | $132K | Form 4 |
| Oct 15, 2024 | Gilad Oren President/CEO · Director | Purchase | 250 | $725 | Form 4 |
| Oct 14, 2024 | Duey Marc Director | Purchase | 190 | $490 | Form 4 |
| Oct 11, 2024 | Hamill John P. SrVP/CFO/Prin Fin & Acct Ofcr | Purchase | 50 | $123 | Form 4 |
| Oct 11, 2024 | Seizinger Bernd R. Director | Purchase | 10,000 | $27K | Form 4 |
Hamill John P.
SrVP/CFO/Prin Fin & Acct Ofcr
Date
Mar 12
Shares
10,095
Price
—
Value
—
Gilad Oren
President/CEO · Director
Date
Jan 30
Shares
28,100
Price
$0.89
Value
$25K
Hamill John P.
SrVP/CFO/Prin Fin & Acct Ofcr
Date
Jan 30
Shares
5,700
Price
$0.89
Value
$5K
Hamill John P.
SrVP/CFO/Prin Fin & Acct Ofcr
Date
Dec 10
Shares
5,000
Price
$1.17
Value
$6K
Gilad Oren
President/CEO · Director
Date
Apr 3
Shares
2,497
Price
$1.80
Value
$4K
Gilad Oren
President/CEO · Director
Date
Apr 3
Shares
3,003
Price
$1.87
Value
$6K
Hamill John P.
SrVP/CFO/Prin Fin & Acct Ofcr
Date
Mar 27
Shares
3,365
Price
—
Value
—
Gilad Oren
President/CEO · Director
Date
Oct 23
Shares
500
Price
$3.92
Value
$2K
Gilad Oren
President/CEO · Director
Date
Oct 15
Shares
250
Price
$2.90
Value
$725
Hamill John P.
SrVP/CFO/Prin Fin & Acct Ofcr
Date
Oct 11
Shares
50
Price
$2.46
Value
$123
⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar
▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —
About APRE insider trading
APRE insider trades
Aprea Therapeutics, Inc. (APRE) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Hamill John P. (SrVP/CFO/Prin Fin & Acct Ofcr), Gilad Oren (President/CEO · Director), Duey Marc (Director). Over the past 12 months, 3 insiders have filed transactions with the SEC. APRE insiders have been primarily buying, which may reflect pre-scheduled Rule 10b5-1 plan executions.
For Aprea Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →
Frequently asked questions
APRE insider trading · 5 questionsThe insiders of Aprea Therapeutics, Inc. (APRE) include executives and directors such as Hamill John P. (SrVP/CFO/Prin Fin & Acct Ofcr), Gilad Oren (President/CEO · Director), Duey Marc (Director), among others. Over the past 12 months, 3 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.
▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026